Brief: GENFIT SA Says Phase 1 Results Confirm G1090N Has A Favorable Safety And Tolerability Profile
06/01/2026 17:35
Jan 6 (Reuters) - GENFIT SA GNFT.PA: GENFIT SA: PHASE 1 RESULTS CONFIRM INVESTIGATIONAL DRUG-CANDIDATE G1090N HAS A FAVORABLE SAFETY AND TOLERABILITY PROFILE GENFIT SA - G1090N TO ADVANCE INTO PHASE 2 PROOF-OF-CONCEPT STUDIES ACROSS THE ACLF CONTINUUM Source text: ID:nGNX1LLJpW Further company coverage: GNFT.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genfit SA
See all newsFrance's Genfit H1 revenue falls due to absence of milestone payments
French and Benelux stocks-Factors to watch on September 15
Brief: Genfit SA - Advances Nangibotide In Phase 2 Clinical Investigation In Aclf
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Genfit March 31 Cash And Cash Equivalents EUR 136.1 Million